Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Albuterol
Drug ID BADD_D00056
Description Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.[Label,A174379,A174400]
Indications and Usage For symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, and other chronic bronchopulmonary disorders such as COPD.
Marketing Status Discontinued; Prescription
ATC Code R03AC02; R03CC02
DrugBank ID DB01001
KEGG ID D02147
MeSH ID D000420
PubChem ID 2083
TTD Drug ID D0K5CB
NDC Product Code 59651-333; 64980-443; 64980-442; 69238-1345; 69543-290; 51079-657; 70771-1512; 71205-898; 69543-291; 59651-334; 70771-1511; 70710-1062; 71205-899; 69238-1344; 70710-1061
Synonyms Albuterol | Salbutamol | 2-t-Butylamino-1-(4-hydroxy-3-hydroxy-3-hydroxymethyl)phenylethanol | Ventolin | Sultanol | Albuterol Sulfate | Proventil
Chemical Information
Molecular Formula C13H21NO3
CAS Registry Number 18559-94-9
SMILES CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Rhinitis11.01.13.004; 22.07.03.006--
Saliva altered07.06.01.004--Not Available
Skin disorder23.03.03.007--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Stomatitis07.05.06.005--
Strangury20.02.02.017--Not Available
Supraventricular tachycardia02.03.03.012--
Tachycardia02.03.02.007--Not Available
Tachycardia foetal02.03.02.017; 18.03.02.005--Not Available
Tension19.06.02.005--Not Available
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Throat irritation07.05.03.004; 22.02.05.013--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Tongue discolouration07.14.02.006--Not Available
Tongue ulceration07.14.01.003--Not Available
Tracheitis11.01.13.007; 22.07.03.009--
Tremor17.01.06.002--
Type I hypersensitivity10.01.03.006--Not Available
Upper respiratory tract infection11.01.13.009; 22.07.03.011--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vascular resistance systemic13.14.03.019--Not Available
Vasodilatation23.06.05.006; 24.03.02.003--Not Available
Vertigo04.04.01.003; 17.02.12.002--
Vomiting07.01.07.003--
Wheezing22.03.01.009--
Musculoskeletal disorder15.03.01.004--Not Available
Emotional distress19.04.02.008--Not Available
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene